Hansa Biopharma: Update after Q1 with our revised outlook - Redeye

Redeye updates its outlook on Hansa Biopharma, anticipating gradual launch support during 2023 and supporting pipeline progress over the next 12 months. We make a negative revision after the recent Q1 2023 result mainly because Hansa is experiencing a period of slower patient enrolment despite the expanding market access. Our Base Case is SEK165 (175) with a Bull Case of SEK390 (400) and a Bear Case of SEK45 (45).

Länk till analysen i sin helhet: https://www.redeye.se/research/895943/hansa-biopharma-update-after-q1-with-our-revised-outlook?utm_source=finwire&utm_medium=RSS